Janssen's Stelara overtakes Takeda's Entyvio as the leading alternative MOA in Crohn's Disease but pressure is on to maximize IBD value in advance of pipeline drugs from Celgene mongersen ozanimod RocheGenentech etrolizumab and Pfizer Xelja

EXTON Pa. June 13 2017 PRNewswire Spherix Global Insights announces the release of RealWorld Dynamix Biologic Switching in IBD which engaged 187 gastroenterologists to conduct an indepth review of over 1000 IBD patients that recently switched between biol...